Impact of First-Line Antifungal Agents on the Outcomes and Costs of Candidemia

Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 04/2012; 56(7):3950-6. DOI: 10.1128/AAC.06258-11
Source: PubMed

ABSTRACT Candida species are the leading causes of invasive fungal infection among hospitalized patients and are responsible for major economic burdens. The goals of this study were to estimate the costs directly associated with the treatment of candidemia and factors associated with increased costs, as well as the impact of first-line antifungal agents on the outcomes and costs. A retrospective study was conducted in a sample of 199 patients from four university-affiliated tertiary care hospitals in Korea over 1 year. Only costs attributable to the treatment of candidemia were estimated by reviewing resource utilization during treatment. Risk factors for increased costs, treatment outcome, and hospital length of stay (LOS) were analyzed. Approximately 65% of the patients were treated with fluconazole, and 28% were treated with conventional amphotericin B. The overall treatment success rate was 52.8%, and the 30-day mortality rate was 47.9%. Hematologic malignancy, need for mechanical ventilation, and treatment failure of first-line antifungal agents were independent risk factors for mortality. The mean total cost for the treatment of candidemia was $4,743 per patient. Intensive care unit stay at candidemia onset and antifungal switch to second-line agents were independent risk factors for increased costs. The LOS was also significantly longer in patients who switched antifungal agents to second-line drugs. Antifungal switch to second-line agents for any reasons was the only modifiable risk factor of increased costs and LOS. Choosing an appropriate first-line antifungal agent is crucial for better outcomes and reduced hospital costs of candidemia.

Download full-text


Available from: Kyong Hwa Park, Apr 10, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is an ever-growing importance for critical assessment of benefits and harms of various strategies with regards to antibiotic stewardship, infection control, molecular detection of pathogens and adequate treatment of multidrug-resistant organisms in ICUs. Ongoing financial constraints globally, changing demographics with an increasing and aging population and the slow introduction of new antibiotics make the utilisation of the best available evidence and goal-directed strategies essential in the ICU setting. This review will summarise findings from some of the recent major publications in the area of infectious diseases with emphasis on the role of behaviour change strategies for infection control purposes, the role of biomarkers such as C-reactive protein and procalcitonin, and the impact of molecular diagnostics in clinical decision-making. Furthermore, we will update readers on some recent findings in relation to invasive fungal infections, community-acquired pneumonia and ventilator-associated pneumonia in ICU patients.
    Critical care (London, England) 12/2012; 16(6):242. DOI:10.1186/cc11421
  • [Show abstract] [Hide abstract]
    ABSTRACT: A non-covalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ~20-50%. AmB was in a highly aggregated state with an aggregation ratio often above 2.0. This complex (AmB-PGA) was shown to be stable and to have reduced toxicity to human red blood cells and KB cells compared to the parent compound; cell viability was not affected at an AmB concentration as high as 200 µg/mL respectively. This AmB-PGA complex retained AmB activity against intracellular Leishmania major amastigotes in the differentiated THP-1cells with an EC50 of 0.07±0.03-0.08±0.01 μg/mL which is similar to Fungizone® (EC50 of 0.06±0.01 µg/mL). The anti-leishmanial in vitro activity of the complex against L. donovani was retained after storage at 37°C for 7 days in the form of a solution (EC50 of 0.27±0.03 to 0.35±0.04 µg/mL) and for 30 days as a solid (EC50 of 0.41±0.07 to 0.63±0.25 µg/mL). These encouraging results indicate that the AmB-PGA complex has the potential for further development.
    Molecular Pharmaceutics 12/2012; 10(3). DOI:10.1021/mp300339p · 4.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A copolymer was used as a platform for solubilisation of an anti-leishmanial agent. A non-covalent complex of amphotericin B (AmB) and poly(vinylpyrrolidone-co-methacrylic acid) (PVM) sodium salt was prepared from a N-hydroxysuccinimide (NHS) active ester precursor polymer in an effort to improve the therapeutic index of AmB. Leishmaniasis is a neglected disease that can be effectively treated with AmB. Unfortunately AmB is poorly soluble and highly prone to aggregation and degradation. It is also toxic and the lipid formulations of AmB that can mediate this toxicity are too expensive and unstable to use in resource-limited regions of the world. We hypothesised that replacement of the lipids with an appropriate water-soluble polymer would be a viable strategy to address the issues of AmB solubility, toxicity and cost of the final medicine. Copolymer precursors of PVM were prepared using different ratios of the monomers, N-1-vinyl-2-pyrrolidone and N-methacryloxysuccinimide. Complexation of AmB was achieved by hydrolysis of the NHS moiety as a DMSO solution of the copolymer precursor and AmB was diluted with sodium hydroxide and water. The free AmB was removed from the AmB–PVM complex, and then freeze dried to give water-soluble (2 mg mL−1 AmB equivalents) complexes with AmB loadings ranging from 20 to 30 wt%. The AmB–PVM complex reduced the toxicity of AmB towards mammalian cells (THP-1 and KB cells) while retaining its activity against intracellular L. major amastigotes in macrophages derived from THP-1 cells. The EC50 of the complex ranged between 0.08 and 0.18 μg mL−1 which is quite similar to clinical AmB (Fungizone®) (0.06 ± 0.01 μg ml−1). Our results show that there is potential to develop safe and effective AmB–polymer complexes to treat leishmaniasis.
    01/2013; 4(3):584-591. DOI:10.1039/C2PY20425H
Show more